BiotechTube

CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + Hydroxyurea

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumor, Adult

Conditions

Solid Tumor, Adult

Trial Timeline

Oct 2, 2023 → Feb 2, 2026

NCT ID
NCT06063317

About CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + Hydroxyurea

CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + Hydroxyurea is a phase 1 stage product being developed by Imugene for Solid Tumor, Adult. The current trial status is terminated. This product is registered under clinical trial identifier NCT06063317. Target conditions include Solid Tumor, Adult.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06063317Phase 1Terminated

Competing Products

20 competing products in Solid Tumor, Adult

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
25
BT1718Bicycle TherapeuticsPhase 1/2
33
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367Eli LillyPhase 1
33
BBP-398LianBioPhase 1
25

Other Products from Imugene

IMU-131 + Ramucirumab plus Paclitaxel + PembrolizumabPhase 2
44
IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.Phase 1/2
33
Azer-cel + Fludarabine + Cyclophosphamide + IL-2Phase 1
25
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 AntibodyPhase 1
25
CF33-hNIS + Pembrolizumab + Modified FOLFOXPhase 1
25